Importance An overview of rates of axillary pathologic complete response (pCR) for all
breast cancer subtypes, both for patients with and without pathologically proven clinically …

The continuous improvement in cancer care over the past decade has led to a gradual
decrease in cancer-related deaths. This is largely attributed to improved treatment and …

Background Accurate identification of pCR to neoadjuvant chemotherapy (NAC) is essential
for determining appropriate surgery strategy and guiding resection extent in breast cancer …

Understanding molecular mechanisms that dictate B cell diversity is important for targeting B
cells as anti-cancer treatment. Through the single-cell dissection of B cell heterogeneity in …

Neoadjuvant chemotherapy is increasingly used in breast cancer, especially for
downstaging the primary tumor in the breast and the metastatic axillary lymph node …

Background Breast cancer is highly heterogeneous, resulting in different treatment
responses to neoadjuvant chemotherapy (NAC) among patients. A noninvasive quantitative …

Breast cancer is the most frequent cancer in women all over the world. The prognosis is
generally good, with a five-year overall survival rate above 90% for all stages. It is still the …

Until recently, cancer registries have only collected cancer clinical stage at diagnosis, before
any therapy, and pathological stage after surgical resection, provided no treatment has been …

This retrospective pooled analysis aims to identify factors predicting relapse despite a
pathologic complete response (pCR) in patients with breast cancer (BC). 2066 patients with …

Purpose In clinically node-positive (cN+) breast cancer patients, evidence supporting
response-guided treatment after neoadjuvant systemic therapy (NST) instead of axillary …